ICER Hands CMS A Drug Price Negotiation Cheat Sheet On Eliquis, Xarelto
Drug price assessment group ran cost analyses on two of the first 10 drugs selected for Medicare price negotiations, Eliquis and Xarelto, and submitted the report to the US government.
You may also be interested in...
In an interview, Sarah Emond talks about why she is ‘worried’ about cell and gene therapy, when ICER might revise its assessment of obesity drugs, and how CMS could build a reliable and transparent Medicare price negotiation program.
Could Government Negotiated Prices Curtail Access? PBMs And Potential Perverse Incentives Dominate First Medicare Listening Session
Patients and advocacy groups tell Medicare they want lower cost drugs but are concerned that if government negotiations lower list prices, rebate-focused PBMs may preference higher list-price competitors.
A former secretary of the US Department of Veterans Affairs and a senior Biogen executive deliberated at a recent summit the unintended consequences of the US Inflation Reduction Act and politics around the legislation. They likened the first prescription drugs subject to price controls under the IRA to a “TV commercial list.”